Plain-English translation of NCT04303988 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Breast Cancer research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a combination of three medications — , SHR1316, and either cisplatin or carboplatin — in patients with triple-negative breast cancer that has spread to the brain. Researchers want to learn whether this combination can slow or stop the cancer's growth and how well patients tolerate the treatment. You would receive the medication until your cancer stops responding, side effects become too difficult to manage, or you decide to leave the study.
Triple-negative breast cancer is an aggressive form of breast cancer that is harder to treat because it lacks certain protein markers that doctors usually target with therapy. When this type of cancer spreads to the brain, treatment options are very limited, so researchers are testing this new medication combination to give patients a potentially more effective option.
You would visit the research center to receive the three-drug combination intravenously (through an IV). You would continue receiving this treatment in cycles until your cancer progresses, side effects become intolerable, or you choose to withdraw. Throughout the study, doctors would monitor you with blood tests, imaging scans (like MRI), and heart function tests to track how well the treatment is working and how your body is responding.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Fudan University
Enrollment target
~35 participants
Started
March 2020
Primary completion
December 2024
Age range
18 Years – 70 Years
Last updated on clinicaltrials.gov in July 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Jian Zhang, MD
Fudan University